The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded under the ticker “STABL” with the ISIN code SE0013513652 and the warrant is traded under the ticker ”STABL TO1” with the ISIN code SE0013748381.

New units issue prior to listing

The Company’s new issue of SEK 35 million was, in the beginning of 2020, subscribed to approximately SEK 153 million (corresponding to a subscription rate of 436%) and the Company will receive around 830 new shareholders.

Advisors

Mangold Fondkommission AB are financial advisors and Advokatfirman Schjødt are legal advisors

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se

Subscribe

Documents & Links